Roche Laboratories regulatory update

The FDA cleared Roche's Invirase (saquinavir mesylate) protease inhibitor for use in combination with nucleoside analogs in patients with HIV. The product, in combination with nucleoside analogs, increased CD4 count an average of 30-40 cells above entry levels in clinical trial patients over 16 weeks of treatment. ...